---
title: "Merck buys AI drug designs from Isomorphic Labs two days after its $5 billion round"
description: "MSD, Merck & Co. (NYSE: MRK) outside the United States and Canada, carries the clinical and commercial risk and pays an undisclosed upfront, milestones and tiered royalties, while Isomorphic Labs holds a new option to co-fund trials for elevated royalties. Two days after the largest life-science venture round ever, the deal hands Alphabet's (Nasdaq: GOOGL) AI drug spinout its fourth Big Pharma payer before any candidate has entered a human trial."
publisher: "The Inference"
section: "Deals"
published: 2026-11-19T16:34:15.648Z
modified: 2026-11-19T16:34:15.648Z
canonical: https://theinference.org/article/merck-buys-ai-drug-designs-from-isomorphic-labs-two-days-after-its-5-billion-round
language: en
keywords: "Isomorphic Labs, Merck, Alphabet, AI Drug Discovery, Biotech"
---

# Merck buys AI drug designs from Isomorphic Labs two days after its $5 billion round

> MSD, Merck & Co. (NYSE: MRK) outside the United States and Canada, carries the clinical and commercial risk and pays an undisclosed upfront, milestones and tiered royalties, while Isomorphic Labs holds a new option to co-fund trials for elevated royalties. Two days after the largest life-science venture round ever, the deal hands Alphabet's (Nasdaq: GOOGL) AI drug spinout its fourth Big Pharma payer before any candidate has entered a human trial.

## Merck buys designs for an unnamed cancer target

On November 19, [Isomorphic Labs](https://theinference.org/markets/companies/isomorphic-labs), the [Google DeepMind](https://theinference.org/markets/companies/google-deepmind) spinout led by founder and chief executive [Demis Hassabis](https://theinference.org/markets/people/demis-hassabis), winner of the 2024 Nobel Prize in Chemistry for AlphaFold, [agreed to discover small-molecule candidates against an oncology target](https://www.prnewswire.com/news-releases/isomorphic-labs-and-msd-enter-strategic-research-collaboration-302945301.html) neither company will name, together with MSD, [Merck & Co.](https://theinference.org/markets/companies/merck-and-co)'s (NYSE: MRK) trade name outside the United States and Canada [1][2]. Isomorphic runs its IsoDDE drug-design engine over MSD's proprietary data sets and hands back molecular designs; MSD owns everything downstream: preclinical and clinical development, manufacturing and sales [1].

## The clinic stays Merck's risk

Money flows toward the lab. Isomorphic takes an undisclosed upfront payment, then research, development, regulatory and commercial milestones, then tiered royalties on net sales [1]. The term that carries the story is an option for Isomorphic to co-fund development in return for elevated royalties, noted in passing across the deal's coverage [1][3]. George Addona, who heads discovery, preclinical development and translational medicine at MSD Research Laboratories, cast the pairing as "close coordination of wet-lab and dry-lab functions" [1]. Isomorphic sells the designs; Merck buys the risk.

## $7.7 billion raised, no valuation given

The option now has a balance sheet behind it. On November 17 Isomorphic [closed an oversubscribed $5 billion Series C](https://www.msn.com/en-us/money/general/ai-drug-developer-isomorphic-raises-5-billion-in-series-c-round/ar-AA2hE12Z) co-led by Greenoaks and [Sequoia Capital](https://theinference.org/markets/companies/sequoia-capital), with Andreessen Horowitz joining and [Alphabet](https://theinference.org/markets/companies/alphabet) (Nasdaq: GOOGL) investing significantly; the UK BioIndustry Association called it the largest life-science venture raise ever [4][5][6].

The money is earmarked for foundational models, the pipeline and clinical-development infrastructure [5]. [Disclosed funding now stands at $7.7 billion](https://www.alternativeswatch.com/2026/11/19/greenoaks-sequoia-isomorphic-labs-series-c/), after $600 million in March 2025 and a $2.1 billion Series B in May [2]. The valuation went unsaid; Bloomberg reported a $50 billion ask, on top of [the $40 billion or more The Inference reported on October 9](https://theinference.org/article/isomorphic-labs-reported-40-billion-raise-prices-biohub-s-1-8-billion-cell-data-pact) [4][7][8].

*Chart: **Isomorphic's funding has grown from $0.6 billion to $5 billion a round in 20 months** Column chart: Isomorphic Labs' external funding rounds rose from $0.6 billion in March 2025 to $2.1 billion in May 2026 to $5 billion in November 2026.*

*Disclosed external financing, US$ billions: March 2025 first external round led by Thrive Capital, May 2026 Series B, November 2026 Series C co-led by Greenoaks and Sequoia. Sources: Alternatives Watch; Fierce Biotech. [2][10]*

## Four of the top eight drugmakers, zero human trials

[Merck is the fourth Big Pharma name on the roster](https://www.fiercebiotech.com/biotech/isomorphic-labs-adds-merck-ai-drug-discovery-roster-days-after-5b-raise), after [Eli Lilly](https://theinference.org/markets/companies/eli-lilly) and [Novartis](https://theinference.org/markets/companies/novartis) signed 2024 alliances worth about $3 billion combined including milestones and [Johnson & Johnson](https://theinference.org/markets/companies/johnson-and-johnson) followed this year, a partner list spanning four of the top eight drugmakers by revenue [9][10]. No Isomorphic candidate has entered a human trial; its oncology and immunology results are described only as "positive preclinical", with no named first candidate and no clinical date [4][5][10]. The first trial, targeted for end-2026, has already slipped from end-2025 [8].

## The tell is the option

For Merck holders the cost is an undisclosed line beside an in-house discovery organization; for Alphabet holders the payback on a named AI asset arrives as partner fees and royalties, years before any approved medicine. The number to watch is the one MSD did not disclose, and the move is the one Isomorphic now controls: if it co-funds an MSD trial, the $5 billion [4] stops being a research subsidy and starts buying royalty streams.

## Takeaway

Isomorphic Labs collects a fourth Big Pharma payer before a single candidate has entered a human trial, and the term that matters is its new option to pay for part of Merck's trial in exchange for a bigger royalty.

## Sources

1. [PR Newswire, Isomorphic Labs and MSD Enter Strategic Research Collaboration, 19 November 2026](https://www.prnewswire.com/news-releases/isomorphic-labs-and-msd-enter-strategic-research-collaboration-302945301.html)
2. [Alternatives Watch, Greenoaks, Sequoia lead $5bn Series C for AI drug developer Isomorphic Labs, 19 November 2026](https://www.alternativeswatch.com/2026/11/19/greenoaks-sequoia-isomorphic-labs-series-c/)
3. [Yahoo Finance, Merck Partners With Isomorphic Labs to Advance AI-Powered Cancer Drug Discovery, 19 November 2026](https://finance.yahoo.com/healthcare/articles/merck-partners-isomorphic-labs-advance-133619349.html)
4. [Reuters (via MSN), AI drug developer Isomorphic raises $5 billion in Series C round, 17 November 2026](https://www.msn.com/en-us/money/general/ai-drug-developer-isomorphic-raises-5-billion-in-series-c-round/ar-AA2hE12Z)
5. [Pulse 2.0, Isomorphic Labs Raises $5 Billion Series C For AI Drug Discovery Platform, 17 November 2026](https://pulse2.com/isomorphic-labs-raises-5-billion-series-c-for-ai-drug-discovery-platform/)
6. [The Pharma Letter, Isomorphic Labs raises $5 billion Series C, with no drug yet in the clinic, 17 November 2026](https://www.thepharmaletter.com/biotech-news/isomorphic-labs-raises-5-billion-series-c-with-no-drug-yet-in-the-clinic)
7. [HT World, Isomorphic Labs raises US$5bn to take candidates to clinical trials, 18 November 2026](https://htworld.co.uk/news/ai/isomorphic-labs-raises-us5bn-to-take-candidates-to-clinical-trials/)
8. [The Inference, Isomorphic Labs' reported $40 billion raise prices Biohub's $1.8 billion cell-data pact, 9 October 2026](https://theinference.org/article/isomorphic-labs-reported-40-billion-raise-prices-biohub-s-1-8-billion-cell-data-pact)
9. [Fierce Biotech, Isomorphic adds Merck to AI drug discovery roster days after $5B raise, 19 November 2026](https://www.fiercebiotech.com/biotech/isomorphic-labs-adds-merck-ai-drug-discovery-roster-days-after-5b-raise)
10. [Fierce Biotech, Isomorphic Labs raises $5B series C months after $2.1B round, 17 November 2026](https://www.fiercebiotech.com/biotech/isomorphic-labs-raises-5b-series-c-months-after-21b-round)


---

Merck buys AI drug designs from Isomorphic Labs two days after its $5 billion round — The Inference. Canonical: https://theinference.org/article/merck-buys-ai-drug-designs-from-isomorphic-labs-two-days-after-its-5-billion-round
